Business Wire

IL-ZS

Share
ZS Elects Pratap Khedkar to CEO

Global professional services firm ZS today announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firm’s leaders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005232/en/

Khedkar is the third CEO in ZS’s nearly 40-year history. He was elected by his peers, a structure ZS’s founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity and to elevate leaders who embody the company’s dedication to strategy, innovation and client collaboration. He succeeds Chris Wright, who served the firm’s maximum term and will be affiliated with ZS for the next five years as part of its principal emeritus program, focusing on the projects that he’s most passionate about.

Khedkar has held various leadership roles during his 21 years with ZS. Khedkar has led the firm’s global pharmaceuticals and biotechnology practice for nearly a decade, driving growth and market penetration across both established and emerging companies. While heading up the firm’s advanced data science track, he and 250 data scientists helped integrate AI-enabled solutions across many business areas. He’s recently turned his attention to expanding the firm’s healthcare expertise to help clients establish deeper relationships and more effective partnerships across the healthcare ecosystem to improve health outcomes, emphasize a better patient experience and address health disparities.

“Pratap is stepping into this role during an exciting period of growth and change at ZS,” said Wright, who oversaw the company’s 30% growth in 2020. “We’re increasingly being called in by the companies we partner with to identify, advise on and adapt to the next big shifts in their respective industries. I’m confident that under Pratap’s counsel, the best days at ZS are ahead of us.”

“Chris has done a tremendous job during his tenure as CEO, and I’ll be leaning on his knowledge and guidance in the months and years ahead,” Khedkar said. “His greatest legacy is preserving the culture that our founders worked so hard to create. His emphasis on continually investing in our people has ‘kept the magic alive,’ as he’s been known to say.”

Khedkar will oversee the global acceleration and scaling of ZS’s portfolio of life sciences and healthcare work. He plans to ramp up investments in the firm’s technology, digital analytics and software capabilities across healthcare and in other industries. To continue working alongside clients and staying connected to market trends, Khedkar is making a critical adjustment to the leadership operating model by appointing 20-year ZS veteran Sandra Forero to the firm’s newly created chief operating officer role.

Forero has held various leadership positions at ZS, including client service lead for two major biopharma clients, head of the firm’s integrated analytics practice, founding chair of the people and culture team, chair of the inclusion and diversity council and elected member of ZS’s shareholder’s council since 2015.

“I welcome Sandra to this role and look forward to partnering with her. She’s a trusted and respected leader at ZS who is incredibly passionate about driving client impact, ensuring the growth and success of our people and stewarding our culture,” Khedkar said. “Our commitment to excellence and solving complex problems is critical for both personal and firm growth and has made ZS what it is today. And, we’re strongly positioned to continue doing more of what ZS does best: helping companies and their customers thrive.”

“At ZS, we work together to leverage our deep expertise in industry and functional areas, analytics and technology to cultivate a culture of innovation and collaboration for client benefit,” said Jaideep Bajaj, chairman of the board at ZS. He held the position of CEO from 2003 to 2012. “I’m excited about ZS’s next era with Pratap leading a strong team that’s focused on creating value for our clients.”

Khedkar holds a Ph.D. in artificial intelligence from the University of California, Berkeley and a Bachelor of Technology degree in computer science from the Indian Institute of Technology Delhi.

About ZS

ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 10,000-plus ZSers in 28 offices worldwide, we’re passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye